HTG Molecular Diagnostics (HTGM) Jumps Up 118%; Announces Next Event in RNA Profiling Webcast Series

HTG Molecular Diagnostics (HTGM), a life science company, jumped up 118% today, upon announcing the next event in its RNA profiling in Drug Discovery KOL webcast series.

The latest webinar featured a presentation from Dr. Robert Spitale, who discussed the use of RNA profiling in the drug discovery process.

The HTG Therapeutics team will present results from the application of its transcriptome-informed drug discovery process. You can register for the presentation here.

HTGM is a member of the PRISM MedDiagnostics Index, which is up 2% for the day, and the only PRISM Index with a positive day.

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

About the Author

HTG Molecular Diagnostics (HTGM) Jumps Up 118%; Announces Next Event in RNA Profiling Webcast Series

Investors Prism